You are here

From the other Journals

The articles in this section have been identified by the editor of the resource centre, Jim Thornton, Professor of Obstetrics and Gynecology at Nottingham University, UK, as key publications in the area of Obstetrics Gynecology.

All key publications are available online with external links plus editorial commentaries and titles written specifically for the EJOG resource centre by Prof. Jim Thornton.


  • Editor's comment: Prof. Jim Thornton: The addition of misoprostol to 3rd stage oxytocin does not prevent postpartum haemorrhage

    A large, 1,721 participant, randomized controlled trial from France comparing oxytocin plus oral misoprostol with oxytocin alone, for post-partum haemorrhage prophylaxis in the 3rd state of labour was negative.  Rates of moderate and severe bleeding were not reduced, and side effects were significantly higher in the misoprostol group.

    Active Management of the Third Stage of Labor With a Combination of Oxytocin and Misoprostol to Prevent Postpartum Hemorrhage: A Randomized Controlled Trial

    Obstet Gynecol. 2016 Oct;128(4):805-11
  • Editor's comment: Prof. Jim Thornton: Oil is better than water

    A randomised trial from the Netherlands among 1119 infertile women, compared hystero-salpingography with oil or water contrast medium. Ongoing pregnancies and live births were significantly higher in the oil contrast group. RR 1.37; 95% CI 1.16-1.61, and RR 1.38; 95% CI 1.17-1.64 respectively.

    Oil-Based or Water-Based Contrast for Hysterosalpingography in Infertile Women

    N Engl J Med. 2017 May 25;376(21):2043-2052.
  • Editor's comment: Prof. Jim Thornton: Closing in on the “pre-eclampsia gene”

    The InterPregGen group of researchers performed genome wide sequencing studies on 2,658 offspring from pre-eclamptic pregnancies and controls, using cohorts collected from UK, Iceland, Finland and Norway.  After testing over 7 million sequence variations they identified one, rs4769613, which was associated with the disease at the P = 3.2 x 10-8 significance level. Unlike previous purported associations this one is likely to be real. rs4769613 is located near the FLT1 locus.

    Variants in the fetal genome near FLT1 are associated with risk of preeclampsia

    McGinnis R et al.

    Nature Genetics, Volume:49,Pages:1255–1260, 2017
  • Editor's comment: Prof. Jim Thornton: ASPRE trial

    It has long been known that low dose aspirin (typically 75mg daily) prevents pre-eclampsia, although the effect is modest, only a 10% reduction. The ASPRE trial identified women at increased risk of pre-eclampsia using a screening algorithm and randomised then to aspirin 150mg at night or placebo from 14 weeks at the latest.  Although the screening algorithm performed somewhat less well than anticipated, the aspirin was more effective than previous trials in preventing pre-term pre-eclampsia (Odds ratio 0.38; 95% confidence interval, 0.20 - 0.74).

    Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia

    Rolnik DL, Wright D, Poon LC, O’Gorman N, Syngelaki A, de Paco Matallana C, et al.

    N Engl J Med. 2017 Aug 17;377(7):613-622. doi: 10.1056/NEJMoa1704559. Epub 2017 Jun 28.
  • Editor's comment: Prof. Jim Thornton: WOMAN trial; tranexamic acid reduces deaths due to post-partum bleeding

    One of the largest ever trials in obstetrics, the WOMAN trial of tranexamic acid to treat post-partum haemorrhage has reported.  Tranexamic acid reduces death due to bleeding with no adverse effects. When used as a treatment for postpartum haemorrhage, tranexamic acid should be given as soon as possible.

    Woman trial collaborators (2017) Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.  

    Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.

    Lancet. 2017 May 27;389(10084):2105-2116. doi: 10.1016/S0140-6736(17)30638-4. Epub 2017 Apr 26.
  • Exercise in pregnancy!

    Vincenzo Berghella, Gabriele Saccone

    American Journal of Obstetrics and Gynecology, Volume 216, Issue 4, April 2017, Pages 335–337
  • A randomized clinical trial of exercise during pregnancy to prevent gestational diabetes mellitus and improve pregnancy outcome in overweight and obese pregnant women

    Wang C, Wei Y, Zhang X, Zhang Y, Xu Q, Sun Y, Su S, Zhang L, Liu C, Feng Y, Shou C, Guelfi KJ, Newnham JP, Yang H

    Am J Obstet Gynecol. 2017 Apr;216(4):340-351. doi: 10.1016/j.ajog.2017.01.037. Epub 2017 Feb 1.
  • Editor's comment: Prof. Jim Thornton:
    The results of one of the largest trials ever performed in pregnancy, the INFANT trial of a computerised alert in addition to continuous electronic fetal heart rate monitoring versus CEFM alone, were publish online on March 21st.  The results were negative. The computerised alert system does not reduce any adverse outcomes.

    Computerised interpretation of fetal heart rate during labour (INFANT): a randomised controlled trial

    Brocklehurst P, Field D, Greene K, Juszczak E, Keith R, Kenyon S, Linsell L, Mabey C, Newburn M, Plachcinski R, Quigley M, Schroeder E, Steer P.

    Lancet. 2017 Apr 29;389(10080):1719-1729. doi: 10.1016/S0140-6736(17)30568-8. Epub 2017 Mar 21.
  • Fetal brain MRI

    Prof Paul D Griffiths, Michael Bradburn, Prof Michael J Campbell, Prof Cindy L Cooper, Ruth Graham, Deborah Jarvis, Prof Mark D Kilby, Gerald Mason, Cara Mooney, Prof Stephen C Robson, Prof Allan Wailoo on behalf of the MERIDIAN collaborative group

    Volume 389, No. 10068, p538–546, 4 February 2017
  • New WHO fetal growth charts

    Kiserud T et al.

    (2017) The World Health Organization Fetal Growth Charts: A Multinational Longitudinal Study of Ultrasound Biometric Measurements and Estimated Fetal Weight. PLoS Med 14(1): e1002220. doi:10.1371/journal.pmed.1002220

Pages

E-Alert

Subscribe to our E-Alert to stay informed of all new content as it's published on this platform.


Share


News

Commentaries by Editor Prof. Jim Thornton